GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Debt-to-Asset

CTOR (Citius Oncology) Debt-to-Asset : 0.05 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Debt-to-Asset?

Citius Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Citius Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.80 Mil. Citius Oncology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $84.37 Mil. Citius Oncology's debt to asset for the quarter that ended in Sep. 2024 was 0.05.

Citius Oncology Debt-to-Asset Historical Data

The historical data trend for Citius Oncology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Debt-to-Asset Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Debt-to-Asset
- - 0.05

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Debt-to-Asset - - 0.05

Competitive Comparison of Citius Oncology's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Debt-to-Asset falls into.


;
;

Citius Oncology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Citius Oncology's Debt-to-Asset for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 3.8) / 84.369
=0.05

Citius Oncology's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 3.8) / 84.369
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology  (NAS:CTOR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Citius Oncology Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Debt-to-Asset
Comparable Companies
SCYX RMTI SXTC MRMD ETST CPIX ASRT INCR INIS DRRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.